Cardiff Oncology, Inc. CRDF 深 滬
等待開盤 01-30 09:30:00 美东时间
1.698
+0.078
+4.81%
華盛通- 最 高1.83
- 今 開1.69
- 成交量 177.61万股
- 最 低 1.6701
- 昨 收 1.62
- 總市值 1.13亿
- 52周最高 4.99
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.62
- 委 比 -20.60%
- 總股本 6652.59万
- 歷史最高 977.76
- 量 比 1.58
- 振 幅 9.87%
- 歷史最低 0.701
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Cardiff Oncology Names Mani Mohindru Interim CEO
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support
01-28 00:17
Cardiff Oncology Announces Update From CRDF-004, Phase 2 Clinical Trial Evaluating Onvansertib In Combination With SoC Regimens In Patients With 1L RAS- mCRC
- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with
01-27 20:07
Cardiff Oncology Reports Early Onvansertib Monotherapy Activity In Phase 1 CMML Trial Ahead Of ASH 2025 Poster Presentation
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an
2025-12-09 05:06
Cardiff Oncology Q3 EPS $(0.17) Beats $(0.20) Estimate, Sales $120.000K Beat $112.500K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.20) by 15.42 percent. This is a 32 percent increase over losses of $(0.25) per share from the
2025-11-07 05:37
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology宣布其管理层将参加2025年9月的三场投资者会议，包括Wells Fargo、Morgan Stanley和H.C. Wainwright的年度医疗与投资大会。公司通过PLK1抑制剂开发抗癌疗法，重点治疗结直肠癌、胰腺癌等。会议详情见公司网站。
2025-08-28 20:05
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $10
HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target from $18 to $10.
2025-08-06 20:06
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?
Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of PFS benefit.
2025-07-31 03:27
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
2025-07-31 01:07
Cardiff Oncology Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $121.00K Beat $92.86K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 19.23 percent increase over losses of $(0.26) per share from
2025-07-30 04:14
